The Sixth Lugano Conference: Basic science papers by Ong, S. T. et al.
Annals of Oncology 8 (Suppl. 2): S1-S2,1997.
Introduction
The Sixth Lugano Conference: Basic science papers
S. T. Ong,1 R. Stupp2 & J. E. Ultmann1
1
 Section of Hematology I Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA; 2 Center for Oncology, University Hospital,
Lausanne, Switzerland
The Lugano conferences have in the past stressed both
clinical and basic science research in the study of lym-
phomas. This year has been no exception, and we wit-
nessed an obvious increase both in the number and scien-
tific content of the presentations and abstracts in the
meeting. Herein we include some of the interesting pre-
sentations in the basic sciences and pathological classifi-
cation of lymphomas.
Since the last meeting in 1993, an important new clas-
sification of lymphomas has emerged. Originally pub-
lished in Blood in 1994, the REAL classification is an
attempt by the International Lymphoma Study Group to
develop a consensus list of currently recognizable lym-
phoid neoplasms that can be diagnosed with available
morphologic, immunologic, and genetic techniques, and
which have distinct clinical features. Certainly, the REAL
classification is an excellent review of the known lympho-
ma entities and, significantly, directs our thinking toward
treating each lymphoma as a different disease, with its
own distinctive genotype and biologic behavior, each of
which may require a specific therapy. However, as the
authors pointed out in their original article, this is only an
interim classification, and remains as imperfect as our
knowledge of lymphomas. Ongoing efforts are being
made to improve the clinical relevance of biologically
based classifications by consensus meetings between
pathologists and clinicians. With better understanding of
the underlying causes of malignancy, and the additional
genetic 'hits' that confer more aggressive behavior and
resistance to chemotherapy, we may actually find our-
selves adopting even more detailed classifications in the
future. The explosion of research in molecular oncology
is the force driving us in this direction. The question at
present is to determine if such a classification better
serves the patient in terms of improved assessment of
risk factors and improved treatment. Such questions are
being answered with retrospective analyses, such as those
that were presented by Fisher and Armitage at the 1996
conference, and ongoing prospective trials.
One distinctive entity, MALT lymphoma, is a partic-
ularly instructive example. The recognition of this lym-
phoma by Isaacson in the 1980s and its association with
H. pylori infections paved the way for the astounding
regressions that are seen when the associated H. pylori
infections are treated. A number of papers confirmed
that early-stage and low-grade disease can be effectively
treated in 90% of cases with a combination of antibiotics
and anti-ulcer therapy. The relapse and long-term sur-
vival rates have yet to be described. The recognition of
MALT lymphoma as a distinct clinicopathologic entity,
its association with H. pylori, and the disease-specific
therapy have been a remarkable advance encouraged by
careful pathologic and epidemiologic studies. A special
issue of Annals of Oncology that includes many of the
presentations at the 1996 conference on MALT lympho-
mas has been published recently.
Since the last conference yet another infectious agent,
Kaposi's sarcoma-associated herpes virus, or human
herpes virus 8, has been strongly associated with a rare
but clinicopathologically distinct lymphoma: the primary
effusion lymphomas. The studies by Knowles, in which
Southern blotting or PCR-based techniques were used
to look for KSHV, demonstrated the specificity of this
virus in body cavity-based lymphomas but not in AIDS-
and non-AIDS-related lymphomas or Hodgkin's lym-
phoma. These findings are obviously important, de-
scribing a new infectious agent and its possible role in
the etiology of these rare lymphomas. Ultimately they
may also herald a cause-directed therapeutic approach
that combines antiviral therapy and conventional chemo-
therapy.
The 1996 conference also witnessed the more careful
characterization of known proto-oncogenes in lympho-
ma: bcl-\, bcl-2, bcl-3, and bcl-6. The recognition of
mantle-cell lymphomas (within the REAL classification)
and the realization that these lymphomas overexpress the
cyclin Dl gene, at the bcl-\ locus, in the majority of cases,
further justifies its recognition as a distinct biologic entity.
We also learned that the transformation to diffuse large-
cell lymphoma by follicular lymphoma is associated with
somatic mutations of the bcl-2 gene. Whether this is
responsible for the more aggressive behavior of the large-
cell lymphomas has yet to be shown. Falini and others
showed us using immunohistochemical techniques that
normal germinal centers express bcl-6, as well as follicu-
lar, large-cell, and Burkitt's lymphomas. Interestingly, it
was also demonstrated that the protein is also expressed
in L & H cells of lymphocyte-predominant Hodgkin's
disease.
Two presentations suggested answers to long-standing
questions regarding the biology of Hodgkin's disease: the
cell of origin of the Reed-Sternberg cell and the role,
if any, of eosinophils in the pathogenesis of Hodgkin's proliferation by way of its CD30 ligand. This paper sug-
disease. Rajewksy et al. presented data for the B-cell gests a role for the eosinophil in the pathogenesis of
origin of the Reed-Sternberg cell. These elegant data Hodgkin's disease, and suggests another potential thera-
were derived from single-cell PCR studies in which they peutic target in this disease.
showed VH gene rearrangements in Reed-Sternberg cells As evidenced by the following selection of papers, the
from 12 out of 13 patients with classical Hodgkin's dis- quality of the science presented at the Lugano confer-
ease. Furthermore, these cells demonstrated a high level ences continues to be of the highest standards. The inter-
of somatic mutations, suggesting an origin from the ger- actions between basic scientists and clinicians are one of
minal center cell. A paper by Pinto et al., investigating the most valuable aspects of these conferences, and will
the role of eosinophils in Hodgkin's disease, suggested in future ensure both the success of the meetings and
that they-were capable of promoting Reed-Sternberg cell their important role in the battle against lymphoma.
